EUVIMEDEUVIMED entdecken
EditorialKommentar

Is Autologous Hematopoietic Stem Cell Transplant Better Than High-Efficacy Disease-Modifying Therapies for Relapsing Multiple Sclerosis?

Jeffrey A Cohen, Anne H Cross

JAMA Neurology · 2023

DOI: 10.1001/jamaneurol.2023.0467 ↗

Kurz gefasst

Editorial in der Zeitschrift JAMA Neurology, 2023. Verfasst von Jeffrey A Cohen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Mellen Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio. Hauptthemen laut MEDLINE: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingHematopoietic Stem Cell TransplantationHumansTreatment OutcomeTransplantation, Autologous

Autor:innen und Institutionen

  • Mellen Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio.
  • Department of Neurology, Washington University, St Louis, Missouri.

Zitieren

APA

Cohen, J. A., & Cross, A. H. (2023). Is Autologous Hematopoietic Stem Cell Transplant Better Than High-Efficacy Disease-Modifying Therapies for Relapsing Multiple Sclerosis?. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2023.0467

Vancouver

Cohen JA, Cross AH. Is Autologous Hematopoietic Stem Cell Transplant Better Than High-Efficacy Disease-Modifying Therapies for Relapsing Multiple Sclerosis?. JAMA Neurology. 2023. doi:10.1001/jamaneurol.2023.0467

BibTeX
@article{Cohen2023,
  author = {Cohen, Jeffrey A and Cross, Anne H},
  title = {Is Autologous Hematopoietic Stem Cell Transplant Better Than High-Efficacy Disease-Modifying Therapies for Relapsing Multiple Sclerosis?},
  journal = {JAMA Neurology},
  year = {2023},
  doi = {10.1001/jamaneurol.2023.0467}
}
Kostenlos starten →